Connect with us

Media & Technology

Major Move on MRPI (Mera Pharmaceuticals, Inc) As Benny Doro Proprietor of All Your Foods & Subsidiary All Your Meals Becomes New Majority Owner

Published

2 years ago

on

MRPI (Mera Pharmaceuticals, Inc) has skyrocketed out of deep sub penny land in recent months and continues to see new highs as Benny Doro becomes majority owner of the Corporation and All Your Foods and its operating subsidiary All Your Meals go public on the OTC. The stock has been heading northbound in a hurry and is starting to get noticed by big time investors and the right kind of penny stock speculators who have been heavily accumulating. Trading has been heavy in recent days as MRPI easily topped $4.5 million in dollar volume on Friday alone as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than MRPI has. 

All Your Meals delivers fresh chef-created meals to individuals and businesses in the Lower Mainland of BC. As a chef-prepared meal delivery service, All Your Meals is uniquely positioned unlike other existing meal subscription companies that merely offer ingredients with the accompanying recipes. The Company’s daily prepared, delicious and easy meals have proven to address the need among a large and growing consumer demographic who simply do not have the time to cook or an interest in cooking. The management of All Your Meals has incorporated a US Subsidiary, All Your Foods USA Inc, which has just completed its acquisition of Chop & Chisel, an established meal prep delivery with over $650,000 in annual revenue in all-stock deal (time). Founded in 2015, Chop & Chisel is a healthy meal delivery serving Charlotte, Huntersville, North Carolina and surrounding areas. The acquisition endows All Your Foods USA with existing database of subscribers that generate steady and growing revenue in a fast-growing market. The acquisition includes three retail locations and an established delivery footprint in the regions.  

MRPI (Mera Pharmaceuticals, Inc) operating out of Boca Raton, Florida, is a clean shell that was originally incorporated in Colorado before changing its state of incorporation to Delaware. As of last week, Benny Doro, a successful New York based businessman with over twenty years of experience in venture capital, early-stage financing, entertainment media management and financial payment software development and the proprietor of All Your Meals; a thriving subscription fresh meal service for over four years located in Burnaby, British Colombia. 

On March 17, 2021, Gary Spaniak entered into a Stock Purchase Agreement under which Benny Doro purchased 1,000,000 shares each of Preferred A, Preferred B and 1,000 Preferred C shares of preferred stock. This gives Doro majority voting control of the corporation. On March 17, 2021, Gary Spaniak resigned from all officer and director positions with the corporation and Benny Doro is hereby appointed as interim director, president, secretary and treasurer and Rafi Markarian as director to serve until the next regularly scheduled election. 

All Your Meals| All Your FoodsThe initial 8k was filed on December 12 and describes a reverse merger whereby Burnaby, BC based All Your Foods and its operating subsidiary All Your Meals will go public. All Your Meals delivers fresh chef-created meals to individuals and businesses in the Lower Mainland of BC. As a chef-prepared meal delivery service, All Your Meals is uniquely positioned unlike other existing meal subscription companies that merely offer ingredients with the accompanying recipes. The Company’s daily prepared, delicious and easy meals have proven to address the need among a large and growing consumer demographic who simply do not have the time to cook or an interest in cooking. 

Progress to-date: Since its establishment in 2015, All Your Meals has quickly progressed to becoming a reputable brand with a large base of loyal members. Its proprietary meal and membership system serve as a valuable asset going forward. Combined with an acquired solid operational infrastructure, logistics management and delivery network, these allow the Company to develop a capacity and operational knowledge for large-scale production and market expansion. 

The management of All Your Meals has incorporated a US Subsidiary, All Your Foods USA Inc, which has just completed its acquisition of Chop & Chisel, an established meal prep delivery with over $650,000 in annual revenue in all-stock deal (time). Founded in 2015, Chop & Chisel is a healthy meal delivery serving Charlotte, Huntersville, North Carolina and surrounding areas. The acquisition endows All Your Foods USA with existing database of subscribers that generate steady and growing revenue in a fast-growing market. The acquisition includes three retail locations and an established delivery footprint in the regions. All Your Foods USA will considerably enhance Chop & Chisel’s operation by its technology infrastructure including membership management, delivery tracking and scalability. 

To Find out the inside Scoop on MRPI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

MRPI

On March 17, 2021, Gary Spaniak entered into a Stock Purchase Agreement under which Benny Doro purchased 1,000,000 shares each of Preferred A, Preferred B and 1,000 Preferred C shares of preferred stock. This gives Doro majority voting control of the corporation. On March 17, 2021, Gary Spaniak resigned from all officer and director positions with the corporation and Benny Doro is hereby appointed as interim director, president, secretary and treasurer and Rafi Markarian as director to serve until the next regularly scheduled election. 

Benny Doro is a successful New York based businessman with over twenty years of experience in venture capital, early-stage financing, entertainment media management and financial payment software development. In 2002, Mr. Doro became a partner in Marketview Financial Group, Inc. a private investment banking firm based on Wall Street. Mr. Doro has been instrumental in developing a number of projects from fruition thought funding through to taking them public. Mr. Doro is also a co- founder and President at Universal Vision Group, a leading provider e-commerce software providing international multi-currency pre-paid cards to both corporate users and consumers offering a complete Tier 1 pre-paid card issuer processing infrastructure. The company is also a e-commerce Payments Systems Provider with multiple banking relations and clients across America and internationally. Mr. Doro serves on the Board of Directors at Pyramid Media, Inc. (Pyramid Records), an entertainment company with multiple artists that provides major distribution through INgrooves Fontana and Universal Music Group Distribution, the largest distributor of music in the world. 

In 1995, Mr. Doro founded NextLevel Productions Inc., a multi-media advertising and marketing company. As CEO of the company, he managed multiple clients including negotiating content deals with artists such as Madonna, Van Halen, U2, KISS, Britney Spears, Jessica Simpson, and Sony Fanfire. In 2001, NextLevel merged with Wiremix Media Inc., and became the largest digital advertising company in the online gambling industry with over 65 clients. In 2002, Mr. Doro negotiated the sale of NextLevel to a publicly traded company. From 1985 to 2000, Mr. Doro performed in and managed a Rock and Roll band under the tutelage of Paul Stanley from KISS, which saw him performing in venues world-wide, while providing him with priceless insight into the entertainment and music industries. Mr. Doro was also an officer and director of Atlantic Acquisition II, Inc., from (since June 29, 2020), and Atlantic Acquisition I, Inc. (from Dec. 29, 2020 to Feb. 2018) a blank check both of which a blank check which recently went effective and is behind in its reporting obligations. 

Rafi Markarian is the VP of finance and business development for All Your Foods USA. He has been instrumental in financing various company and help negotiate many of the earlier partnerships. Previously Mr. Markarian has been involved in several other high tech groups bringing financing and helping negotiate some of the agreements. With over 35 years of financial experience Mr. Markarian continues to be a key partner in the company’s ongoing growth. 

For more on MRPI Subscribe Right Now!

MRPI (Mera Pharmaceuticals, Inc) has skyrocketed out of deep sub penny land in recent months and continues to see new highs as Benny Doro becomes majority owner of the Corporation and All Your Foods and its operating subsidiary All Your Meals go public on the OTC. The stock has been heading northbound in a hurry and is starting to get noticed by big time investors and the right kind of penny stock speculators who have been heavily accumulating. Trading has been heavy in recent days as MRPI easily topped $4.5 million in dollar volume on Friday alone as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than MRPI has. All Your Meals delivers fresh chef-created meals to individuals and businesses in the Lower Mainland of BC. As a chef-prepared meal delivery service, All Your Meals is uniquely positioned unlike other existing meal subscription companies that merely offer ingredients with the accompanying recipes. The Company’s daily prepared, delicious and easy meals have proven to address the need among a large and growing consumer demographic who simply do not have the time to cook or an interest in cooking. The management of All Your Meals has incorporated a US Subsidiary, All Your Foods USA Inc, which has just completed its acquisition of Chop & Chisel, an established meal prep delivery with over $650,000 in annual revenue in all-stock deal (time). Founded in 2015, Chop & Chisel is a healthy meal delivery serving Charlotte, Huntersville, North Carolina and surrounding areas. The acquisition endows All Your Foods USA with existing database of subscribers that generate steady and growing revenue in a fast-growing market. The acquisition includes three retail locations and an established delivery footprint in the regions. MRPI has quickly established itself as a volume leader in small caps and has momentum, heavy liquidly and a fast-growing shareholder base that continues to bid the stock higher.  We will be updating on MRPI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MRPI.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in MRPI either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

4 days ago

on

June 4, 2023

By

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by 3D Animation Production Company from Pixabay

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

1 week ago

on

May 29, 2023

By

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

3 weeks ago

on

May 19, 2023

By

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.